Cite
CD20-specific chimeric antigen receptor-expressing T cells as salvage therapy in rituximab-refractory/relapsed B-cell non-Hodgkin lymphoma.
MLA
Cheng, Qian, et al. “CD20-Specific Chimeric Antigen Receptor-Expressing T Cells as Salvage Therapy in Rituximab-Refractory/Relapsed B-Cell Non-Hodgkin Lymphoma.” Cytotherapy (Elsevier Inc.), vol. 24, no. 10, Oct. 2022, pp. 1026–34. EBSCOhost, https://doi.org/10.1016/j.jcyt.2022.05.001.
APA
Cheng, Q., Tan, J., Liu, R., Kang, L., Zhang, Y., Wang, E., Li, Y., Zhang, J., Xiao, H., Xu, N., Li, M., Yu, L., & Li, X. (2022). CD20-specific chimeric antigen receptor-expressing T cells as salvage therapy in rituximab-refractory/relapsed B-cell non-Hodgkin lymphoma. Cytotherapy (Elsevier Inc.), 24(10), 1026–1034. https://doi.org/10.1016/j.jcyt.2022.05.001
Chicago
Cheng, Qian, Jingwen Tan, Rui Liu, Liqing Kang, Yi Zhang, Erhua Wang, Ying Li, et al. 2022. “CD20-Specific Chimeric Antigen Receptor-Expressing T Cells as Salvage Therapy in Rituximab-Refractory/Relapsed B-Cell Non-Hodgkin Lymphoma.” Cytotherapy (Elsevier Inc.) 24 (10): 1026–34. doi:10.1016/j.jcyt.2022.05.001.